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Abstract
We describe a rapid method to accurately measure the cytotoxicity of mammalian cells upon
exposure to various drugs. Using this assay, we obtain survival data in a fraction of the time
required to perform the traditional clonogenic survival assay, considered the gold standard. The
dynamic range of the assay allows sensitivity measurements on a multi-log scale allowing better
resolution of comparative sensitivities. Moreover, the results obtained contain additional
information on cell cycle effects of the drug treatment. Cell survival is obtained from a
quantitative comparison of proliferation between drug-treated and untreated cells. During the
assay, cells are treated with a drug and, following a recovery period, allowed to proliferate in the
presence of BrdU. Cells that synthesize DNA in the presence of bromodeoxyuridine (BrdU)
exhibit quenched Hoechst fluorescence easily detected by flow cytometry; quenching is used to
determine relative proliferation in treated versus untreated cells. Finally, the multi-well setup of
this assay allows the simultaneous screening of multiple cell lines, multiple doses, or multiple
drugs to accurately measure cell survival and cell cycle changes after drug treatment.
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1. Introduction
Survival of cells upon exposure to toxic agents is an important phenotypic measure used to
understand the biological importance of certain proteins and pathways in either preventing
or enabling cell survival after toxic stress. For example, key proteins involved in DNA
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repair or the DNA damage response have been identified by measuring the effect of
silencing or over-expressing these proteins on cell survival after DNA damage. The gold
standard for assessing the survival of cells after drug treatment in such experiments
continues to be the clonogenic survival assay that is extremely sensitive and has a dynamic
range of several orders of magnitude. Unfortunately, it suffers from being very low
throughput as well as time and labor intensive. Typically, the clonogenic survival assay
takes 10-14 days and requires a large number of cell culture plates, thus limiting its practical
application to a few cell lines and to a limited number of doses or agents. Moreover, for cell
lines grown in suspension, or for those that fail to form colonies, the clonogenic survival
assay is done by either monitoring growth from single cells or by following their ability to
form colonies in soft agar. These approaches are even more time intensive taking up to 2-3
weeks to complete a single experiment. Currently, the only available high-throughput
techniques for measuring sensitivity involve the correlation of viability to membrane
permeability (trypan blue or propidium iodide exclusion) or measurement of metabolic
activity (e.g. the MTT assay). Unfortunately, metabolic activity primarily reflects
mitochondrial function; in addition changes in metabolic activity do not always correlate
well with cell viability after treatment, and do not differentiate between cytotoxic and static
effects after treatment. Similarly, membrane permeability only takes into account cells that
undergo cell death after treatment and fails to identify sensitivity due to activation of a static
program such as arrest or senescence [1]. Perhaps more importantly, these methods have an
inherently limited dynamic range for detection of sensitivity, generally less than a single
order of magnitude versus three or four orders of magnitude for the clonogenic survival
assay.
In this paper, we describe a rapid method for measuring the drug sensitivity of cells with a
dynamic range comparable to that of the clonogenic survival assay. This assay has a much
higher throughput compared to traditional clonogenic survival assays. In addition to
obtaining survival information, it can also be used to deduce cell cycle effects of drug
treatment. This method is based on the fact that the fluorescence of Hoechst, a dye that
preferentially binds AT-rich regions in the DNA, is quenched when bromodeoxyuridine
(BrdU), a thymine analog, is incorporated into DNA [2, 3]. Cells that have divided zero, one
or two times in the presence of BrdU can be differentiated based on the level of quenched
Hoechst fluorescence, thus giving a measure of cell proliferation [4]. In a previous report,
Poot et al. [5] took advantage of the Hoechst quenching property of BrdU to measure
survival of cells after exposure to a DNA damaging agent. We have extensively modified
the technique to be performed in a multi-well format (96-well plate for suspension cells and
24-well plate for adherent cells), drastically decreasing the setup time and reducing the
number of cells required for a survival curve to as little as 106−3×106 cells. Furthermore, we
have broadened the scope of the assay so that it can simultaneously be used with different
cell types and different cytotoxic agents. The assay can be completed within half the time
taken to perform a clonogenic survival assay while maintaining high sensitivity and a
dynamic range of three to four logs of magnitude.
Figure 1 shows a concise representation of the steps involved in the assay. After cells are
treated they are allowed to recover for the duration of two doubling times and subsequently
allowed to proliferate (if they can) for the duration of another two doubling times in the
presence of BrdU. To make our approach amenable to screening multiple agents with
diverse mechanisms of action, we allow cells two doubling times after treatment for toxicity
to present. This allows for simultaneous detection of the toxicity of agents that act
immediately versus those that require formation of intermediates to slowly build up in cells.
As an example, various DNA damaging agents are dependent on replication for toxicity to
occur, and several days may need to pass prior to an observable phenotypic response. The
duration of time prior to BrdU addition can be optimized depending on the agents to be
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tested. At the end of the assay, cells are gently lysed to obtain nuclei that are stained with
propidium iodide (PI) and Hoechst dye. Nuclei fluorescence is measured by flow cytometry
to quantify the percentage of cells that have proliferated in the presence of BrdU. The
relative proliferation rate of treated samples compared to untreated controls gives a measure
of the sensitivity of cells to treatment. The ease, economy and efficiency of this assay will
enable rapid progress in systematic approaches to understanding the biological importance
of many proteins and pathways whose modulation leads to an observed phenotype after
exposure to cytotoxic agents.
2. Materials and Methods
2.1 Cell culture
The human lymphoblastoid cell lines TK6 [6] and TK6 derivatives (MT1 [7] and
TK6+MGMT[8]) were grown in suspension in RPMI medium supplemented with 10%
equine serum, 1% l-glutamine and 1% penicillin-streptomycin. TK6 and MT1 cell lines
were derived from the same parent and both lack the DNA repair protein MGMT whereas
the TK6+MGMT cell line contains reconstituted MGMT. A genetically diverse set of human
lymphoblastoid suspension cell lines were obtained from the Coriell Institute for Medical
Research and cultured in RPMI medium (Invitrogen) supplemented with 15% FBS, 1%
penicillin-streptomycin and 1% L-glutamine. The cell lines were numbered 1-24 for ease of
handling. The Coriell catalog numbers for the cell lines 1-24 are respectively, GM15029,
GM13036, GM15215, GM15223, GM15245, GM15224, GM15236, GM15510, GM15213,
GM15221, GM15227, GM15385, GM15590, GM15038, GM15056, GM15072, GM15144,
GM15216, GM15226, GM15242, GM15268, GM15324, GM15386, GM15061. The
adherent U87MG glioblastoma cell line was obtained from ATCC (Rockville, MD) and
grown in DMEM medium supplemented with 10% fetal bovine serum, 1% l-glutamine and
1% penicillin-streptomycin.
2.2 Determining the optimal BrdU concentration
Cells are grown in the presence of different concentrations of BrdU (0-100μM) for one
doubling time. Cells are then lysed and stained as described below with Hoechst and
propidium iodide for flow cytometry analysis. The optimal BrdU dose is determined as that
which quenched Hoechst fluorescence of G1 cells by half after one doubling time. This dose
allows the effective resolution of cells that have undergone one division after BrdU addition
from those that have undergone none or two divisions after addition. This optimal dose was
determined as 45μM for the lymphoblastoid suspension cell lines and 20μM for the U87MG
cell lines.
2.3 Cell cycle profile analysis by flow cytometry
BrdU is sometimes known to cause a G2/M arrest in cultured human cells. TK6, TK6
derivatives and U87MG cell lines were grown in the presence of the optimal BrdU
concentration for at least two doubling times, during which samples were collected at
multiple time points, washed with cold PBS and fixed overnight in cold 100% ethanol.
Fixed cells were washed with PBS+1% BSA, resuspended in PBS+1%BSA containing
propidium iodide (50μg/ml) and immediately analyzed by flow cytometry to obtain cell
cycle profiles. None of the cell lines showed a G2/M arrest when grown in the presence of
BrdU. If however such an arrest is observed, the effect can be overcome by adding
deoxycytidine at an equal concentration as the added BrdU [3].
2.4 Drug treatment
Cell lines were treated in duplicate at multiple doses of BCNU from a 100mM stock solution
in 100% ethanol. A maximum of six doses were assayed and therefore 12 wells
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accommodated duplicate exposures for each survival curve. Treatment was performed in
serum free media for one hour, after which the drug was washed away and the cells were
returned to fresh serum-containing media. This treatment scheme can be accommodated for
cytotoxic agents that require longer exposure times as well as short-lived agents that do not
require to be washed away after treatment. The drug treatment procedure is described below
for both suspension and adherent cell lines.
Suspension cells—Before drug treatment, cells were grown to mid-log phase (6×105
cells/ml for TK6 and its derivatives). 270μl of cells at a density of 4.5×105 cells/ml were
plated in each well of one row of a round-bottom 96-well plate. If multiple cell lines were
assayed, each cell line was plated in one row of a 96-well plate in serum free media. The
drug was diluted to 10× the final dose concentrations in serum free media in another 96-well
plate. 30μl of the solution with 10× the desired dose was transferred to each well in the 96-
well plate containing cells, after which the cells were incubated at 37°C for 1h. After 1h,
cells were spun down at 1200rpm for 5min, drug-containing media was removed using a
multi-channel pipette and the cells were washed with 200μl warm 1×PBS per well. The cells
were then centrifuged and resuspended in 300μl of warm fresh media containing serum,
transferred to a flat-bottom 96-well plate and incubated at 37°C for the duration of two
normal doubling times. If the drug is not to be washed away, the experiment is set up in a
flat-bottom 96-well plate at a density of 1.7×105cells/ml in serum containing media, and the
washing step is omitted.
Adherent cells—Before drug treatment, U87MG cells were grown to 80% confluence,
washed with warm 1×PBS, trypsinized and diluted to 4×104cells/ml. Due to the limited
number of adherent cells that can attach to the wells in a 96-well plate, U87MG were treated
in 24 well plate format. The rest of the assay is continued in a 96 well format, as described
below, making sample processing and data collection faster and more efficient. 1ml of the
diluted cells were plated in each well of a 24-well plate and cells were allowed to attach
overnight at 37°C, 5% CO2. One such 24-well plate was set up for each cell line that was
assayed. At the time of treatment, the cells were removed from the incubator and the media
replaced with 900μl of warm, fresh serum-free media. The drug was diluted to 10× the final
dose concentrations and 100μl of the 10× drug was added per well such that there were
duplicate wells per dose and six doses including the untreated control. The cells were
returned to the incubator for 1h after which the drug-containing media was replaced with
warm serum-containing media. The cells were returned to the incubator for a period
equivalent to two doubling times for normally growing cells.
2.5 Bromodeoxyuridine Addition
After allowing cells to recover for two doubling times after drug treatment, the cells are
grown in the presence of BrdU for another two doubling times. The optimal BrdU
concentration was determined to be 45μM for TK6 and its derivatives and 20μM for
U87MG cells as described above. If BrdU concentration is greater than 20μM, then BrdU
must be replenished every 12 hours. Therefore, after the first two doubling times, BrdU was
added to TK6 and TK6 derivatives at a concentration of 45μM (from a 10mM stock
solution) and replenished by simply adding BrdU to each well every 12 hours for the
duration of two normal doubling times. Similarly BrdU was added to U87MG cells at a
concentration of 20μM. Since cells become photosensitive upon BrdU addition, care must
be taken to keep cells in the dark at all times post BrdU addition.
2.6 Nuclei isolation and staining for flow cytometry
At the end of four doubling times after drug treatment, cells were transferred to a v-bottom
96-well plate. For suspension cells, the cells were transferred directly to a v-bottom 96-well
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plate using a multi-channel pipette. For adherent cells, the cell plate was spun down at
1500rpm for 5min to pull down any unattached cells. The media was removed and replaced
with 100μl of 0.25% trypsin EDTA. Trypsin was quenched with 200μl of serum-containing
media and the cells from each well in the 24-well plate were transferred to individual wells
of a v-bottom 96-well plate. Once transferred both cell types were spun down at 1500rpm
for 5min, media was removed with a multi-channel pipette and cells were washed with cold
1×PBS. The cells were then resuspended in 300μl of 1× lysis/staining buffer (0.1M Tris HCl
pH 7.5, 0.1% Igepal CA-60, 1mM CaCl2, 5mM MgCl2, 0.2%BSA (w/v), 1.2μg/ml Hoechst
33258 and 1×104 chicken erythrocyte nuclei (CEN)/ml) and incubated on ice for 15 minutes
after which 6μl of 200μg/ml propidium iodide was added to each well using a multi-channel
pipette. Two wells containing only the lysis/staining buffer and propidium iodide are also
prepared as blank controls. Samples were mixed well using a multi-channel pipette and
analyzed on a BD LSR II flow cytometer equipped with a 96-well plate robot arm.
2.7 Data collection
Events were visualized on the side scatter vs. forward scatter plot to gate out debris (Figure
2A), and gated on the PI-height vs. PI-area plot to exclude doublets that fall below the
diagonal (Figure 2B). 30,000 events that passed these two criteria were collected and viewed
on a PI-Area vs. Hoechst-Area plot (Figure 2C). During data collection, the voltages for PI
and Hoechst were adjusted to position CEN at the (30K, 30K) point to make subsequent data
analysis easier.
3. Results
3.1 Detecting cells that have undergone zero, one or two cell divisions after drug treatment
BCNU is a DNA damaging agent commonly used in the clinic to treat glioblastoma despite
the fact that it can have severe side effects on hematopoietic cells [9, 10]. We used the multi-
well assay to test the BCNU sensitivity of the human lymphoblastoid cell lines TK6 and
TK6 derivatives (MT1 and TK6+MGMT) that grow in suspension and the human U87MG
glioblastoma cell line that grows attached. All data were analyzed using FlowJo (TreeStar
Inc). For each cell line and drug dose, the debris and doublets were gated out as described in
Figure 2. The remaining events were observed on a PI-Area vs. Hoechst-Area plot. Figure 3
delineates the regions corresponding to cells that are in the first, second or third cell cycle
after treatment, recovery and incubation with BrdU. As seen in Figure 3A, Hoechst
fluorescence of cells decreases as they replicate their DNA in the presence of BrdU.
Therefore, as the cells replicate and divide, they move from the region labeled 1st cell cycle
leftwards to the region labeled 2nd cell cycle, and so on. For each sample, gates were drawn
as in Figure 3C and the number of events in each gate was determined.
3.2 Calculating the fraction of proliferated cells after drug treatment
For each cell type and dose assayed, the number of events in each of the regions
corresponding to the second and third cell cycle was used to calculate the number of
proliferating cells in the sample as shown below in formula 1.
Formula 1
½*(#events in cell cycle 2/#CEN) + *(#events in cell cycle 3/#CEN)
The formula calculates the total number of cells that have divided after drug treatment by
halving the number of cells in the second cell cycle (these cells have undergone one cell
division) and dividing the number of cells in the third cell cycle by four (these cells have
undergone two cell divisions). Since all samples of equal volume were spiked with the same
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number of CEN, the number of CEN counted per sample is proportional to the volume of
sample used for flow cytometry data collection. Therefore the cell density of proliferating
cells is calculated by dividing the total number of proliferating cells per sample by the
number of CEN counted in that sample. Comparing the density of proliferated cells in a
treated sample with that in an untreated sample gives the % control growth value that is used
to plot a survival curve.
3.3 The multi-well assay has a large dynamic range, yielding log scale
killing for suspension and adherent cell lines treated with a cytotoxic agent
BCNU's efficacy as a chemotherapeutic agent arises from its ability to generate extremely
cytotoxic DNA inter-strand crosslinks [11]. DNA crosslinks are formed in a multistep
process, the first of which is the formation of O6-chloroethylguanine lesions [12]. The O6-
methylguanine methyl transferase (MGMT) protein is known to remove chloroethyl adducts
from the O6 position of guanine [13, 14]. Thus, MGMT provides protection against BCNU-
induced cytotoxicity, and cells lacking MGMT are particularly sensitive to this agent
[15-17]. With this in mind, we used our multi-well assay to measure BCNU sensitivity of
cell lines either lacking MGMT (TK6, MT1 and U87MG) or expressing MGMT
(TK6+MGMT) to determine the range of sensitivity accurately measured by the assay.
BCNU sensitivity of suspension (TK6 and MT1) and adherent (U87MG) cell lines that each
lack MGMT was measured using our multi-well assay. The TK6 and MT1 cell lines have
previously been shown to be extremely BCNU sensitive using the clonogenic survival assay
as shown in Figure 4A [8]. Results from the multi-well assay, shown in Figure 4B, are
remarkably similar to those from the colony-forming assay. Additionally, we measured
BCNU sensitivity of the TK6+MGMT cell line (the TK6 cell line reconstituted with
MGMT) using the multi-well assay and found that TK6+MGMT cells show extreme
resistance to BCNU, as expected (Figure 4B). We also tested the assay on adherent cells by
measuring BCNU sensitivity of the adherent U87MG glioblastoma cell line that lacks
MGMT [18]. Again, as expected the U87MG cells showed extreme BCNU sensitivity
(Figure 4C), also with log-scale killing.
3.4 Measuring and comparing the cytotoxicity of BCNU in a multiple cell
lines
Recent efforts in our group have focused on identifying the range of alkylation sensitivity in
24 lymphoblastoid cell lines derived from unrelated, healthy individuals of diverse ancestry
[19]. This study demonstrated that cells derived from healthy individuals display an
unexpectedly wide range of sensitivity to the alkylating agent N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG), a drug with a mechanism of action analogous to the cancer
chemotherapy agent temozolomide. Temozolomide is frequently used in the treatment of
certain brain cancers and lymphomas [20, 21]. This range in sensitivity has profound
implications in the context of inter-individual differences in response to chemotherapy, with
some patients demonstrating innate resistance or sensitivity to treatment. Here, we used our
multi-well assay to assess the range in sensitivity of the same 24 genetically diverse
lymphoblastoid cell lines to the chemotherapeutic agent BCNU. The cell lines were grown
in suspension and assayed in a 96-well format as described. Cells were exposed to multiple
doses of BCNU in biological triplicates to obtain the survival curves shown in Figure 5. The
set of 24 genetically varied cell lines displayed a wide range of sensitivities, with survival
measured over three orders of magnitude. From this study, we identified cell lines that had
extreme sensitivity or resistance to BCNU, which have been used for further investigation of
factors affecting BCNU sensitivity or resistance (Valiathan et. al. in preparation). The multi
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well assay described here allows for rapid screening of panels of cell lines for their
sensitivity to a wide variety of cytotoxic agents. This information will aid in identifying
mechanisms of resistance and sensitivity to commonly used cytotoxic chemotherapeutic
agents.
3.5 The multi-well assay detects cell-cycle effects of drug treatment
Flow cytometry plots obtained using our assay for U87MG cells treated with BCNU show
that with increasing doses of BCNU, there is not only a decrease in the total number of cells
but that this decrease is also accompanied by a steady increase in the fraction of cells in late
S and G2/M phase of the first cell cycle (Figure 6). From these observations we can
conclude that at higher BCNU doses surviving cells are unable to divide during the BrdU
pulse and remain in the region corresponding to the first cell cycle. Moreover, surviving
cells are arrested at late S or G2/M for the entire duration after BrdU addition. A comparison
of these results with previously published results is provided in the discussion below.
4. Discussion
The multi-well assay we describe here produces survival measurements on a multi-log scale
comparable to the clonogenic survival assay. As described in the results section, BCNU
sensitivities of the suspension cell lines TK6 and MT1 are remarkably similar to that
measured by the clonogenic survival assay. Moreover, the TK6+MGMT cell line is
identified as being resistant to BCNU treatment as expected [15, 17]. These results highlight
three important aspects of our assay: i) The assay can measure sensitivity and resistance
equally well, thus yielding accurate results that reflect those obtained from the clonogenic
survival assay; ii) the multi-well assay is capable of measuring cell sensitivity on a multi-log
scale, thus showing the large dynamic range the assay has in contrast to other available
quick assays; iii) the assay can be used to measure cell survival of both suspension and
adherent cell lines to cytotoxic agents, thus increasing its applicability.
The multi-well format of the assay has a reduced setup time allowing one to simultaneously
assay either a large number of cell lines, doses or agents. This greatly improves cell survival
measurement efficiency to yield results in a fraction of the time and in a less labor-intensive
manner as compared to the clonogenic survival assay. As demonstrated, the assay enabled us
to measure the sensitivity of a panel of 24 genetically diverse cell lines to multiple doses of
BCNU in biological triplicates, and thus generate survival profiles for the panel of cell lines.
The results showed a wide range of sensitivities across genetically diverse cell lines,
enabling us to identify cell lines with extreme BCNU sensitivity or resistance for further
study (Valiathan et. al. in preparation). In our previous study monitoring MNNG-sensitivity
across the panel of 24 cell lines, growth measurements at one time point following exposure
to one dose was used to assess sensitivity, and we observed only a 9-fold change in
sensitivity from most sensitive to most resistant [22]. The approach described here, gave us
the relative sensitivity of the cell lines to within three orders of magnitude, analogous to
clonogenic survival assays, within a fraction of the time. Furthermore, comparing the most
sensitive and most resistant cells lines from our previous studies with MNNG and the
current study with BCNU, allows us to assess whether the sensitivity of cells to cytotoxic
agents is specific to the class of cytotoxic agents used, or simply represents the response to
cytotoxic damage in general. As an example, while cell line 6 was shown to be the most
sensitive to MNNG in our previous report, this cell line clusters with the least sensitive cell
lines after BCNU treatment. In contrast, cell line 4 appears to be among the most sensitive in
both cases. The difference observed in cell line 6 may reflect differences in the ability to
repair DNA interstrand crosslinks that are induced by BCNU but not by MNNG. Currently,
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we are investigating the mechanisms of BCNU resistance and sensitivity in the two most
resistant and two most sensitive cell lines (Valiathan et. al. in preparation).
The ability to gather proliferation data from a small number of cells and with higher
throughput, as compared to traditional clonogenic survival assays, has the potential to be
used to measure the sensitivity of cell sub-populations that have previously proven difficult
to analyze. Glioblastoma is both the most common and most malignant form of brain cancer.
Despite aggressive therapy, this tumor frequently displays a resistant phenotype. A sub-
population of cells, dubbed glioblastoma stem cells, have been hypothesized to contribute to
this resistant phenotype [23, 24]. Glioblastoma stem cells are identified and enriched from
primary tumor samples due to their ability to form suspended cell aggregates, termed
neurospheres, in certain culture conditions [24]. The protocol described here would enable
screening for compounds to target this resistant sub-population regardless of whether or not
they can form colonies.
In addition to inducing cell death, many cytotoxic agents affect regular cell cycle
progression, with cells undergoing arrest either in the G1, S or G2/M phases of the cell
cycle. The nature of the arrest changes with the drug or cell line used, and provides insight
into mechanisms of drug action and possible ways to modify cell sensitivity to a particular
drug. The data obtained using our assay showed that the BCNU-induced decrease in
surviving U87MG glioblastoma cells is accompanied by a concomitant arrest in late S/G2
phase of the cell cycle (Figure 6). Previous studies have shown that U87MG cells show an
accumulation of cells in late S or G2/M after BCNU treatment [25] (assayed by PI staining
and cell cycle profile analysis by flow-cytometry). Traditional clonogenic survival assays, as
well as more recent high-throughput survival assays, yield no information on possible cell
cycle arrest from the drug treatment. Any such cell cycle effects have been determined by
separate experiments usually using flow cytometry. In comparison, results from the multi-
well assay we describe here are rich in cell-cycle information, and provide added insight into
the long-term cell cycle effects of the drug treatment.
In conclusion, we have presented a rapid and efficient method that takes advantage of
current flow cytometry technology and properties of proliferating cells to measure the
sensitivity of both suspension and adherent cells to cytotoxic agents. The flexibility of the
method, its large dynamic range and its broad applicability makes it a powerful tool with
great potential in many different applications including both small and large scale screening
of sensitivity of numerous cell lines to known or suspected toxic agents.
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Abbreviations
PI propidium iodide
CEN chicken erythrocyte nuclei
BCNU 1,3-bis(2-chloroethyl)-1-nitrosourea
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Highlights
• A rapid FACS based survival assay
• Sensitivity as a function of quenched Hoechst fluorescence by BrdU
incorporation
• Method allows for simultaneous detection of cell cycle effects after drug
treatment
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Figure 1. Timeline of key steps in the experimental procedure
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Figure 2.
(A) Side scatter vs. forward scatter plot shows the position of nuclei, CEN and debris. All
events in gate R1 are to be included in the data collection and analysis steps; (B) PI-Height
vs. PI-Area plot shows the doublet events below the diagonal that must be excluded. Events
in gate R2 are included in the data collection and analysis steps; (C) PI-Area vs. Hoechst-
Area plot of events included in gates R1 and R2. PI and Hoechst channel voltages must be
adjusted to position CEN at (30K, 30K) or any other practical coordinates for all samples.
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Figure 3.
(A) PI-Area vs. Hoechst-Area plot showing the regions that would contain nuclei in the first
cell cycle (CC1)- light grey, second cell cycle (CC2)- dark grey, third cell cycle (CC3)
black; (B) Plot showing the G1, S and G2 populations for each cell cycle. G11, S1, G21 are
G1, S and G2 in cell cycle 1 and so on; (C) Example of a sample for which the CEN and cell
cycle gates have been drawn.
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Figure 4.
(A) Killing curves for BCNU treatment of TK6 and MT1 cell lines using the traditional
clonogenic survival assay reproduced from [8]; (B) Killing curves for BCNU treatment of
the TK6, MT1 and TK6+MGMT cell lines using the multi-well assay; (C) Killing curves for
BCNU treatment of the U87MG cell line using the multi-well assay.
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Figure 5.
Survival curves for a panel of 24 genetically diverse lymphoblastoid cell lines exposed to
multiple doses of BCNU (80, 60, 40, 20, 10 and 0μM). Cell lines are numbered from 1-24
and their corresponding catalog numbers are provided in the MATERIALS AND
METHODS section. The mean of biological triplicates is shown and error bars denote the
standard deviation from the mean.
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Figure 6.
U87MG cells show increasing accumulation of cells in late S/G2 with increasing BCNU
doses of 0μM, 20μM and 60μM (A, B and C respectively). The box in the figures marks the
area corresponding to the late S/G2 region of the first cell cycle which has approximately
double the value of Hoechst and PI fluorescence as compared to the region containing the
G1 cells in the first cell cycle seen in panel A.
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